Several analysts have recently updated their ratings and price targets for First Tracks Biotherapeutics (NASDAQ: TRAX):
- 10/16/2026 – First Tracks Biotherapeutics had its price target raised by Leerink Partners from $70.00 to $90.00. They now have an “outperform” rating on the stock.
- 10/13/2026 – First Tracks Biotherapeutics had its “outperform” rating reaffirmed by Evercore Inc. They now have a $70.00 price target on the stock.
- 10/13/2026 – First Tracks Biotherapeutics had its price target raised by Canaccord Genuity Group Inc. from $50.00 to $60.00. They now have a “buy” rating on the stock.
- 10/12/2026 – First Tracks Biotherapeutics had its price target raised by Wells Fargo & Company from $62.00 to $70.00. They now have an “overweight” rating on the stock.
- 10/9/2026 – First Tracks Biotherapeutics had its price target raised by Wells Fargo & Company to $62.00. They now have an “overweight” rating on the stock.
- 10/8/2026 – First Tracks Biotherapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
- 9/30/2026 – First Tracks Biotherapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $50.00 price target on the stock.
- 9/18/2026 – First Tracks Biotherapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $65.00 price target on the stock.
- 9/18/2026 – First Tracks Biotherapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $65.00 price target on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by UBS Group AG. They set a “buy” rating on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
- 9/5/2026 – First Tracks Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 9/3/2026 – First Tracks Biotherapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $57.00 price target on the stock.
- 8/18/2026 – First Tracks Biotherapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $83.00 price target on the stock.
Insider Buying and Selling at First Tracks Biotherapeutics
In other news, Director J. Ware sold 39,265 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $44.78, for a total transaction of $1,758,286.70. Following the sale, the director owned 15,660 shares of the company’s stock, valued at approximately $701,254.80. This trade represents a 71.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.
Read More
- Five stocks we like better than First Tracks Biotherapeutics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
